Loading stock…

Zenas BioPharma, Inc. (ZBIO) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Zenas BioPharma, Inc.

ZBIOMarket cap $1.84BPrice $28.2

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops autoimmune and immunology drugs by licensing promising Chinese-discovered biologics and bringing them to Western markets. Its lead drug obexelimab targets multiple autoimmune diseases at once, betting big on China's overlooked biotech pipeline before Western giants catch on.

In Bastion Portfolios?

52W Return+18%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)-90%1

Rev CAGR (3y)+128%10

Rev CAGR (5y)+115%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-27390%1

Net Income Margin-48438%1

Free Cash Flow Margin-22597%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-199%1

ROA-97%1

Earnings Stabilityna–

GEAR+VERY WEAK5

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV7.42

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-12.3%1

Dividend Yieldna–

Momentum

Short term

1 month return-15%1

3 month return-2%6

YTD return-22%2

Mid term

Price vs 52wHigh63%3

1 year return+9%6

Long term

3 year return+55%6

5 year return+55%6

Risk Shield

Price Risk

Beta0.48

Volatility115%1

Free Cash Flow

Free Cash Flow Margin-22597%1

Free Cash Flow Yield-12.3%1

Quality

ROCE-63%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

ZBIOZenas BioPharma

Revenue FY25$10M

GROWTH RATING↗

AVERAGE60 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y-90%1

Revenue, next 3Y, CAGR+128%10

Revenue, next 5Y, CAGR+115%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 128%/yr over the next 3 years, ahead of most of the market.7/10

Revenue held flat over the last 3 years and is set to grow 128%/yr from here.

The runway holds up: revenue is set to grow 115%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 60% of companies worldwide.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE34 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-2%6

YTD return-22%2

MID & LONG-TERM▾SCORE

% of 52-week high63%3

1-year return+9%6

3-year return+55%6

5-year return+55%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+55% over three years and +55% over five), roughly average for the market.

It's up 9% over the past year, but 37% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-2%).

WEAKNESSES

The stock is underperforming over the past month (-15%) and so far this year (-22%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over the past month and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Zenas BioPharma, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ZBIOZenas BioPharma

Revenue FY25$10M

GROWTH RATING↗

AVERAGE60 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y-90%1

Revenue, next 3Y, CAGR+128%10

Revenue, next 5Y, CAGR+115%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 128%/yr over the next 3 years, ahead of most of the market.7/10

Revenue held flat over the last 3 years and is set to grow 128%/yr from here.

The runway holds up: revenue is set to grow 115%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 60% of companies worldwide.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE34 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-2%6

YTD return-22%2

MID & LONG-TERM▾SCORE

% of 52-week high63%3

1-year return+9%6

3-year return+55%6

5-year return+55%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+55% over three years and +55% over five), roughly average for the market.

It's up 9% over the past year, but 37% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-2%).

WEAKNESSES

The stock is underperforming over the past month (-15%) and so far this year (-22%).

BOTTOM LINE

Mixed Momentum

04Value

Are you paying a fair price for it?

Stop guessing on Zenas BioPharma, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community